Global CRISPR Revolution Gathers Pace, Raising Hopes – And Concerns
Executive Summary
CRISPR technology was invented just five years ago but is so accurate, versatile, easy to use, and inexpensive that it has spread quickly through biology laboratories, giving researchers new tools to interrogate biology and make precise alterations to an organism’s genetic material, offering its potential use in a wide array of therapies.
You may also be interested in...
Sir John Bell: UK Life Science Pact Essential For Post-Brexit Success
Successfully piecing together the agreed life sciences sector deal calls for the UK to embrace high-risk innovation and placing the NHS at its center, says Sir John Bell who helped formulate the pact.
CRISPR Companies Form Pact To Defend, Cross-License Gene Editing Patents
Three CRISPR/Cas9 patent owners and four companies that license the intellectual property – CRISPR, Intellia, Caribou and ERS – signed a formal agreement to protect their patent rights and cross-license necessary IP while a patent interference proceeding is ongoing.
Bayer And CRISPR Form Cutting Edge Gene Editing JV
A big pharma has entered the fray, teaming up with a biotech to create the first long-term stand-alone joint venture exploring the gene-editing technology Crispr-Cas9. German conglomerate Bayer AG and Switzerland-based CRISPR Therapeutics have created a joint venture that will explore the technology in three therapeutic areas.